546: When Speed to Market Matters Most | Richard Steinhart, CFO, Bioxcel Therapeutics
When asked what sets BioXcel Therapeutics apart from other clinical-stage biopharmaceutical companies, CFO Richard Steinhart doesn’t mention a specific drug or therapy. Instead, he describes a system that the company developed to advance the speed with which drugs are commercialized.
According to Steinhart, the biotech company’s system uses artificial intelligence to reveal “hidden connections” that, once exposed, can multiply opportunities for the application of certain drugs.
“Good drug developers can see first connections between drugs and diseases and they are pretty apparent to everyone…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.